Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario M Soldevilla

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 25, 2018
Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma ImmunotherapyMario M Soldevilla, Fernando Pastor
Pharmaceuticals (Basel, Switzerland)|October 21, 2018
Aptamer-iRNAs as Therapeutics for Cancer TreatmentMario M Soldevilla, Daniel Meraviglia-Crivelli de Caso, Ashwathi P Menon, et al.
Oncotarget|December 20, 2015
Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapySandra Hervas-Stubbs, Mario M Soldevilla, Helena Villanueva, et al.
Molecular Therapy. Nucleic Acids|October 19, 2016
In Silico Aptamer Docking Studies: From a Retrospective Validation to a Prospective Case Study-TIM3 Aptamers BindingObdulia Rabal, Fernando Pastor, Helena Villanueva, et al.
Oncoimmunology|September 18, 2018
Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumorsMario M Soldevilla, Helena Villanueva, Naiara Martinez-Velez, et al.
Molecular Therapy. Nucleic Acids|June 13, 2013
CD28 aptamers as powerful immune response modulatorsFernando Pastor, Mario M Soldevilla, Helena Villanueva, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 25, 2018
Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma ImmunotherapyMario M Soldevilla, Fernando Pastor
Pharmaceuticals (Basel, Switzerland)|October 21, 2018
Aptamer-iRNAs as Therapeutics for Cancer TreatmentMario M Soldevilla, Daniel Meraviglia-Crivelli de Caso, Ashwathi P Menon, et al.
Oncotarget|December 20, 2015
Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapySandra Hervas-Stubbs, Mario M Soldevilla, Helena Villanueva, et al.
Molecular Therapy. Nucleic Acids|October 19, 2016
In Silico Aptamer Docking Studies: From a Retrospective Validation to a Prospective Case Study-TIM3 Aptamers BindingObdulia Rabal, Fernando Pastor, Helena Villanueva, et al.
Oncoimmunology|September 18, 2018
Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumorsMario M Soldevilla, Helena Villanueva, Naiara Martinez-Velez, et al.
Molecular Therapy. Nucleic Acids|June 13, 2013
CD28 aptamers as powerful immune response modulatorsFernando Pastor, Mario M Soldevilla, Helena Villanueva, et al.
Pageof 1